Vol. 1 No. 7 (2021)
Reimbursement Recommendations

Durvalumab (Imfinzi)

Published July 28, 2021

Key Messages

  • CADTH recommends that Imfinzi should be reimbursed by public drug plans for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) if certain conditions are met.
  • Imfinzi should only be reimbursed if it is prescribed and monitored by clinicians who have been trained in oncology and immunotherapy, and if the price of Imfinzi is reduced.
  • Imfinzi should only be covered to treat adult patients who have not received previous treatment for ES-SCLC.